The Renin-Angiotensin-Aldosterone System: How the Body Balances Blood Pressure and Sodium

What Triggers the Cascade

The RAAS cascade begins in specialized cells called the juxtaglomerular cells, located in the walls of the afferent arterioles that feed blood into each kidney's glomeruli. These cells act as pressure and flow sensors. Three main signals switch them on: a drop in renal perfusion pressure (sensed directly by stretch receptors in the arteriole wall), reduced sodium chloride delivery to the distal nephron (sensed by the macula densa, a cluster of specialized cells in the nearby distal tubule), and increased sympathetic nervous system activity acting through beta-1 adrenergic receptors. In practice, this means the system activates during dehydration, hemorrhage, low-sodium states, standing up quickly, or any condition, such as heart failure, that reduces effective blood volume reaching the kidneys. Normal systolic blood pressure sits around 120 millimeters of mercury, and even modest sustained drops below this range, or a fall in mean arterial pressure below about 90 millimeters of mercury, can be enough to trigger renin secretion. Because these triggers respond to trends in blood volume and pressure rather than instant readings, RAAS activation is inherently a slower, more deliberative process than the millisecond-to-second baroreflex arc running through the brainstem, which is why the two systems complement rather than duplicate each other.

Renin: The Rate-Limiting Trigger

Once activated, the juxtaglomerular cells release renin, an enzyme (not itself a classical hormone) that is stored in secretory granules and released into the bloodstream in response to the triggers described above. Renin has a short plasma half-life of roughly 10 to 20 minutes, which allows the system to be dynamically responsive rather than locked into a fixed output. Renin's sole job is to cleave angiotensinogen, a plasma protein made continuously by the liver, into a ten-amino-acid fragment called angiotensin I. This step is considered the rate-limiting reaction of the entire cascade: angiotensinogen is normally present in excess, so the amount of circulating renin, not substrate availability, determines how much angiotensin I gets produced. Angiotensin I itself is largely inactive biologically. It circulates until it reaches the lungs, where an enzyme bound to the surface of pulmonary capillary endothelial cells, angiotensin-converting enzyme (ACE), clips off two additional amino acids to produce the far more potent angiotensin II. Because this conversion happens predominantly during a single pass through the pulmonary circulation, the lungs function as an efficient, high-capacity conversion site, ensuring that most angiotensin I entering the lungs emerges as active angiotensin II within seconds.

Angiotensin II: The Powerful Effector

Angiotensin II is one of the most potent vasoconstrictors the body produces, acting primarily through AT1 receptors on vascular smooth muscle throughout the arterial system. By directly constricting arterioles, it raises total peripheral resistance and produces an immediate increase in blood pressure, an effect that begins within seconds of its formation and can raise mean arterial pressure substantially even at low circulating concentrations. But its reach extends well beyond simple vasoconstriction. Angiotensin II stimulates thirst centers in the hypothalamus, promoting water intake. It triggers the release of antidiuretic hormone (vasopressin) from the posterior pituitary, which increases water reabsorption in the kidney's collecting ducts. It acts directly on the proximal tubule to enhance sodium reabsorption. It stimulates sympathetic nervous system activity, reinforcing vasoconstriction and increasing heart rate. And critically, it travels to the adrenal cortex to stimulate the next hormone in the cascade, aldosterone. Angiotensin II also has longer-term structural effects, promoting cardiac and vascular hypertrophy and remodeling, which is part of why chronically elevated angiotensin II, as seen in unmanaged hypertension, contributes to heart failure and vascular damage over years.

Aldosterone and Sodium-Water Retention

Angiotensin II binding to receptors in the zona glomerulosa, the outermost layer of the adrenal cortex, stimulates synthesis and release of aldosterone, a steroid hormone derived from cholesterol. Aldosterone's primary targets are the principal cells of the distal convoluted tubule and, especially, the cortical collecting duct of the nephron. There it binds intracellular mineralocorticoid receptors and, over a timescale of one to several hours (because it works partly by increasing gene transcription of transport proteins), upregulates epithelial sodium channels (ENaC) on the luminal membrane and Na+/K+-ATPase pumps on the basolateral membrane. The net effect is increased sodium reabsorption from the urine back into the blood, with water following osmotically, alongside increased potassium and hydrogen ion secretion into the urine. This expands circulating blood volume, which raises venous return, cardiac output, and blood pressure. Because this mechanism depends on new protein synthesis and gradual accumulation of retained sodium and water, aldosterone's effects build over hours and remain the slowest-acting arm of RAAS, providing sustained, days-long blood pressure support that outlasts the rapid vasoconstrictor action of angiotensin II. This is also why aldosterone excess, as in primary hyperaldosteronism (Conn's syndrome), classically produces hypertension together with low blood potassium (hypokalemia).

Clinical Relevance: Targeting RAAS with Medication

Because RAAS is such a powerful and sustained driver of blood pressure, it is one of the most heavily targeted pathways in cardiovascular medicine. ACE inhibitors (drugs like lisinopril, enalapril, and ramipril, generally identifiable by the '-pril' suffix) block angiotensin-converting enzyme, preventing angiotensin I from being converted into angiotensin II, which reduces both vasoconstriction and aldosterone release. Angiotensin receptor blockers, or ARBs (losartan, valsartan, and similar '-sartan' drugs), work one step further downstream by blocking the AT1 receptor directly, so angiotensin II is still produced but cannot exert its effects. Direct renin inhibitors such as aliskiren block the very first, rate-limiting step. And mineralocorticoid receptor antagonists, including spironolactone and eplerenone, block aldosterone's action at the kidney itself, making them useful both as blood pressure agents and as treatments for heart failure and hyperaldosteronism. All of these drug classes are staples of hypertension management, used when blood pressure persistently exceeds roughly 130 over 80 millimeters of mercury under current guidelines, and are also central to treating chronic kidney disease and heart failure, since chronically overactive RAAS accelerates organ damage in both conditions. A well-known side effect of ACE inhibitors, a dry cough in some patients, arises because ACE also normally breaks down bradykinin, and blocking ACE lets bradykinin accumulate, illustrating how interconnected this cascade is with other physiological pathways.

Frequently asked questions

Try it live

Everything above runs in your browser — open The Renin-Angiotensin-Aldosterone System: How the Body Balances Blood Pressure and Sodium and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.